Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytovir-ADV for Adenovirus Reactivation Post Allo-HSCT
NCT01822093Phase 2Completed
- Sponsor
- Kuur Therapeutics
- Start
- Dec 2012
- Primary completion
- Dec 2016
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Cytovir ADV in adenovirus infection, sponsored by Kuur Therapeutics. Started Dec 2012; status: completed.
02
Drugs
Cytovir ADV
03
Conditions
adenovirus infection
Beyond the preview
Go deeper on NCT01822093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01822093.